Doses of drugs in devices.
Recent experiences with active molecules in spinal fusion devices points to the need to be cautious with dosing regimes and the use of products in off-label situations.
Williams
David
D
Morgan & Masterson, Brussels, Belgium. peggy@morgan-masterson.com
D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants / Q000009:adverse effects*; D004487:Edema / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D013123:Spinal Fusion / Q000009:adverse effects* / Q000295:instrumentation*; D014481:United States
D019485:Bone Morphogenetic Proteins; D004343:Drug Implants